Synlogic Inc (NASDAQ:SYBX) – Investment analysts at Jefferies Financial Group raised their FY2019 earnings per share (EPS) estimates for shares of Synlogic in a research note issued to investors on Tuesday, November 12th. Jefferies Financial Group analyst C. Howerton now expects that the biotechnology company will post earnings per share of ($1.96) for the year, up from their prior estimate of ($2.46). Jefferies Financial Group also issued estimates for Synlogic’s Q4 2019 earnings at ($0.60) EPS, FY2020 earnings at ($1.17) EPS, FY2021 earnings at ($1.09) EPS, FY2022 earnings at ($1.18) EPS and FY2023 earnings at ($1.08) EPS.
Several other equities research analysts have also recently commented on SYBX. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Synlogic in a research note on Monday, September 9th. Zacks Investment Research upgraded Synlogic from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research note on Saturday. Piper Jaffray Companies restated an “overweight” rating and set a $7.00 price target (down previously from $10.00) on shares of Synlogic in a research note on Wednesday. Chardan Capital restated a “buy” rating on shares of Synlogic in a research note on Thursday, September 19th. Finally, Oppenheimer cut Synlogic from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $13.69.
Shares of Synlogic stock opened at $2.10 on Friday. Synlogic has a one year low of $1.96 and a one year high of $11.43. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.43 and a current ratio of 12.70. The business has a 50-day simple moving average of $2.18 and a 200-day simple moving average of $5.31. The company has a market cap of $74.92 million, a PE ratio of -1.03 and a beta of 2.56.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.09. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. The business had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.46 million.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Synlogic by 9.4% during the second quarter. BlackRock Inc. now owns 1,317,063 shares of the biotechnology company’s stock worth $11,986,000 after purchasing an additional 113,665 shares during the last quarter. Vanguard Group Inc. grew its holdings in Synlogic by 0.3% during the second quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock worth $7,013,000 after acquiring an additional 2,558 shares during the period. Northern Trust Corp grew its holdings in Synlogic by 17.1% during the second quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after acquiring an additional 29,401 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Synlogic by 11.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 3,708 shares during the period. Finally, Parametric Portfolio Associates LLC acquired a new position in Synlogic during the second quarter worth $195,000. Institutional investors and hedge funds own 64.98% of the company’s stock.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Recommended Story: Using other technical indicators with support levels
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.